PALATIN TECHNOLOGIES INC
About PALATIN TECHNOLOGIES INC
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$17.3M
- Total assets
- $3.3M
- Market cap
- $25.2M
- Gross margin
- 97.8%
- Operating margin
- -501.0%
- Net margin
- -662.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.5M
- Cost of revenue
- $97.6K
- Gross profit
- $4.4M
- Operating expenses
- $27.0M
- Operating income
- -$22.5M
- Income tax
- $0
- Net income
- -$29.7M
- EPS (basic)
- $-2.02
Balance sheet
- Total assets
- $10.7M
- Current assets
- $9.8M
- Total liabilities
- $10.9M
- Current liabilities
- $9.7M
- Shareholders’ equity
- -$111.5K
Cash flow
- Operating cash flow
- -$31.5M
- Investing cash flow
- $12.5M
- Financing cash flow
- $20.5M
- Net cash flow
- $1.5M
Statements via Polygon.io (SEC filings)
- Market cap
- $25.2M
- Shares outstanding
- 1.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 4, 1993
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $17.3M in FY2025.
- Revenue grew 3706% from FY2020 to FY2024.
- Gross margin of 97.8%, net margin -662.3%.
- Trading 50% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PALATIN TECHNOLOGIES INC.
Write a review
News about PALATIN TECHNOLOGIES INC
News & sentiment via Polygon.io
